Cargando…
Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS)
BACKGROUND: Spirometric diagnosis of chronic obstructive pulmonary disease (COPD) is based on the ratio of forced expiratory volume in 1 second (FEV(1))/vital capacity (VC), either as a fixed value <0.7 or below the lower limit of normal (LLN). Forced vital capacity (FVC) is a proxy for VC. The f...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859418/ https://www.ncbi.nlm.nih.gov/pubmed/27194908 http://dx.doi.org/10.2147/COPD.S104644 |
_version_ | 1782430963471482880 |
---|---|
author | Torén, Kjell Olin, Anna-Carin Lindberg, Anne Vikgren, Jenny Schiöler, Linus Brandberg, John Johnsson, Åse Engström, Gunnar Persson, H Lennart Sköld, Magnus Hedner, Jan Lindberg, Eva Malinovschi, Andrei Piitulainen, Eeva Wollmer, Per Rosengren, Annika Janson, Christer Blomberg, Anders Bergström, Göran |
author_facet | Torén, Kjell Olin, Anna-Carin Lindberg, Anne Vikgren, Jenny Schiöler, Linus Brandberg, John Johnsson, Åse Engström, Gunnar Persson, H Lennart Sköld, Magnus Hedner, Jan Lindberg, Eva Malinovschi, Andrei Piitulainen, Eeva Wollmer, Per Rosengren, Annika Janson, Christer Blomberg, Anders Bergström, Göran |
author_sort | Torén, Kjell |
collection | PubMed |
description | BACKGROUND: Spirometric diagnosis of chronic obstructive pulmonary disease (COPD) is based on the ratio of forced expiratory volume in 1 second (FEV(1))/vital capacity (VC), either as a fixed value <0.7 or below the lower limit of normal (LLN). Forced vital capacity (FVC) is a proxy for VC. The first aim was to compare the use of FVC and VC, assessed as the highest value of FVC or slow vital capacity (SVC), when assessing the FEV(1)/VC ratio in a general population setting. The second aim was to evaluate the characteristics of subjects with COPD who obtained a higher SVC than FVC. METHODS: Subjects (n=1,050) aged 50–64 years were investigated with FEV(1), FVC, and SVC after bronchodilation. Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD(FVC) was defined as FEV(1)/FVC <0.7, GOLDCOPD(VC) as FEV(1)/VC <0.7 using the maximum value of FVC or SVC, LLNCOPD(FVC) as FEV(1)/FVC below the LLN, and LLNCOPD(VC) as FEV(1)/VC below the LLN using the maximum value of FVC or SVC. RESULTS: Prevalence of GOLDCOPD(FVC) was 10.0% (95% confidence interval [CI] 8.2–12.0) and the prevalence of LLNCOPD(FVC) was 9.5% (95% CI 7.8–11.4). When estimates were based on VC, the prevalence became higher; 16.4% (95% CI 14.3–18.9) and 15.6% (95% CI 13.5–17.9) for GOLDCOPD(VC) and LLNCOPD(VC), respectively. The group of additional subjects classified as having COPD based on VC, had lower FEV(1), more wheeze and higher residual volume compared to subjects without any COPD. CONCLUSION: The prevalence of COPD was significantly higher when the ratio FEV(1)/VC was calculated using the highest value of SVC or FVC compared with using FVC only. Subjects classified as having COPD when using the VC concept were more obstructive and with indications of air trapping. Hence, the use of only FVC when assessing airflow limitation may result in a considerable under diagnosis of subjects with mild COPD. |
format | Online Article Text |
id | pubmed-4859418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48594182016-05-18 Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS) Torén, Kjell Olin, Anna-Carin Lindberg, Anne Vikgren, Jenny Schiöler, Linus Brandberg, John Johnsson, Åse Engström, Gunnar Persson, H Lennart Sköld, Magnus Hedner, Jan Lindberg, Eva Malinovschi, Andrei Piitulainen, Eeva Wollmer, Per Rosengren, Annika Janson, Christer Blomberg, Anders Bergström, Göran Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Spirometric diagnosis of chronic obstructive pulmonary disease (COPD) is based on the ratio of forced expiratory volume in 1 second (FEV(1))/vital capacity (VC), either as a fixed value <0.7 or below the lower limit of normal (LLN). Forced vital capacity (FVC) is a proxy for VC. The first aim was to compare the use of FVC and VC, assessed as the highest value of FVC or slow vital capacity (SVC), when assessing the FEV(1)/VC ratio in a general population setting. The second aim was to evaluate the characteristics of subjects with COPD who obtained a higher SVC than FVC. METHODS: Subjects (n=1,050) aged 50–64 years were investigated with FEV(1), FVC, and SVC after bronchodilation. Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD(FVC) was defined as FEV(1)/FVC <0.7, GOLDCOPD(VC) as FEV(1)/VC <0.7 using the maximum value of FVC or SVC, LLNCOPD(FVC) as FEV(1)/FVC below the LLN, and LLNCOPD(VC) as FEV(1)/VC below the LLN using the maximum value of FVC or SVC. RESULTS: Prevalence of GOLDCOPD(FVC) was 10.0% (95% confidence interval [CI] 8.2–12.0) and the prevalence of LLNCOPD(FVC) was 9.5% (95% CI 7.8–11.4). When estimates were based on VC, the prevalence became higher; 16.4% (95% CI 14.3–18.9) and 15.6% (95% CI 13.5–17.9) for GOLDCOPD(VC) and LLNCOPD(VC), respectively. The group of additional subjects classified as having COPD based on VC, had lower FEV(1), more wheeze and higher residual volume compared to subjects without any COPD. CONCLUSION: The prevalence of COPD was significantly higher when the ratio FEV(1)/VC was calculated using the highest value of SVC or FVC compared with using FVC only. Subjects classified as having COPD when using the VC concept were more obstructive and with indications of air trapping. Hence, the use of only FVC when assessing airflow limitation may result in a considerable under diagnosis of subjects with mild COPD. Dove Medical Press 2016-05-02 /pmc/articles/PMC4859418/ /pubmed/27194908 http://dx.doi.org/10.2147/COPD.S104644 Text en © 2016 Torén et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Torén, Kjell Olin, Anna-Carin Lindberg, Anne Vikgren, Jenny Schiöler, Linus Brandberg, John Johnsson, Åse Engström, Gunnar Persson, H Lennart Sköld, Magnus Hedner, Jan Lindberg, Eva Malinovschi, Andrei Piitulainen, Eeva Wollmer, Per Rosengren, Annika Janson, Christer Blomberg, Anders Bergström, Göran Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS) |
title | Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS) |
title_full | Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS) |
title_fullStr | Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS) |
title_full_unstemmed | Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS) |
title_short | Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS) |
title_sort | vital capacity and copd: the swedish cardiopulmonary bioimage study (scapis) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859418/ https://www.ncbi.nlm.nih.gov/pubmed/27194908 http://dx.doi.org/10.2147/COPD.S104644 |
work_keys_str_mv | AT torenkjell vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT olinannacarin vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT lindberganne vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT vikgrenjenny vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT schiolerlinus vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT brandbergjohn vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT johnssonase vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT engstromgunnar vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT perssonhlennart vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT skoldmagnus vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT hednerjan vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT lindbergeva vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT malinovschiandrei vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT piitulaineneeva vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT wollmerper vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT rosengrenannika vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT jansonchrister vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT blomberganders vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis AT bergstromgoran vitalcapacityandcopdtheswedishcardiopulmonarybioimagestudyscapis |